Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of California Los Angeles, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
University of California Los Angeles, Medical Devices Deals, 2011 to YTD 2017 10
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
University of California Los Angeles, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 13
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 14
Trethera Enters into Research Agreement with University of California, Los Angeles 16
Bristol-Myers Squibb Enters into Research Agreement with UCLA 17
BioNano Genomics Enters into Research Agreement with University of California, Los Angeles 18
Zymeworks Enters into Research Agreement with University of California, Los Angeles 19
NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 20
F. Hoffmann-La Roche Enters Into Co-Development Agreement With UCLA’s Jonsson Comprehensive 21
UCLA Medical Center Forms Joint Venture With First Affiliated Hospital Of Medical School 22
Licensing Agreements 23
Diamyd Medical Enters into Licensing Agreement with University of California 23
Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 24
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 25
Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 26
Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 27
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 28
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 29
Fibrocell Science Enters Into Licensing Agreement With University of California 30
Asset Transactions 31
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 31
University of California Los Angeles – Key Competitors 33
University of California Los Angeles – Key Employees 34
University of California Los Angeles – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Joint Venture 37
Recent Developments 38
Government and Public Interest 38
Oct 12, 2017: NIH awards almost $10 million to UCLA Center for Autism Research and Treatment 38
Oct 09, 2017: Combination treatment targeting glucose in advanced brain cancer shows promising results in preclinical study 39
Sep 19, 2017: National Science Foundation awards $800K to researchers using MyLymeData 40
Sep 18, 2017: Behavioral therapy increases connectivity in brains of people with OCD 41
Sep 11, 2017: UCLA Launches CIRM-Funded Cancer Clinical Trial 42
Sep 07, 2017: NIH awards nearly $100 million for Autism Centers of Excellence program 43
Sep 06, 2017: UCLA receives $8.4 million NIH grant to help liver transplant recipients stay healthier longer 45
Aug 14, 2017: UCLA scientists identify a new way to activate stem cells to make hair grow 46
Aug 09, 2017: Stem cell center trainee receives grant to develop nanotechnologies to treat pediatric cancer 48
Jul 26, 2017: UCLA researchers reveal unusual chemistry of protein with role in neurodegenerative disorders 49
Jul 19, 2017: Less Invasive Treatment for Blocked Artery in the Leg is Safe, Review Finds 50
Jul 12, 2017: Electrical stimulation of brain may help people with schizophrenia learn to communicate better 51
Apr 05, 2017: UCLA researchers discover a new cause of high plasma triglycerides 52
Apr 03, 2017: Artificial thymus developed at UCLA can produce cancer-fighting T cells from blood stem cells 53
Mar 09, 2017: Targeting cancer stem cells improves treatment effectiveness and prevents metastasis 54
Feb 27, 2017: Guidelines for treating brain metastases should be overhauled, UCLA study finds 55
Feb 07, 2017: UCLA researchers turn stem cells into somites, precursors to skeletal muscle, cartilage and bone 56
Jan 30, 2017: UCLA will lead $21 million, grant-funded study of epilepsy after traumatic brain injuries 57
Jan 24, 2017: Combination therapy for glioblastoma shows promising results in early-stage research 58
Jan 12, 2017: With $3.2M grant, UCLA researcher to study cancer patients’ response to immunotherapy 59
Jan 10, 2017: Autism biomarker seen as boon for new treatments 60
Dec 22, 2016: With $8.6 million grant from NIH, UCLA-led consortium will map the heart’s nervous system 61
Dec 22, 2016: Protein that activates immune response harms body’s ability to fight HIV 62
Dec 13, 2016: Experimental implant shows promise for restoring voluntary movement after spinal cord injury 63
Oct 26, 2016: Study Questions Benefits of Long-Term Home Oxygen Therapy for COPD Patients with Moderately Low Blood Oxygen Levels 65
Sep 16, 2016: The Cancer Foundation supports a research project on radiotherapy involving LIH 67
Sep 15, 2016: UCLA researchers use stem cells to grow 3-D lung-in-a-dish 68
Sep 01, 2016: New TSRI Method Makes Building ‘One-Handed’ Drugs Easier than Ever 69
Aug 25, 2016: UCLA-led Study Sheds New Light on the Complex Genetics of Autism 71
Jul 22, 2016: UCLA Duchenne muscular dystrophy research receives grant from California’s stem cell agency 73
Jul 21, 2016: Three-drug combinations could help counter antibiotic resistance, UCLA biologists report 74
Jul 14, 2016: Cancer-fighting gene immunotherapy shows promise as treatment for HIV 76
Jun 20, 2016: Nonprofit co-founded by UCLA to form national institute to improve efficiency in manufacturing 77
May 31, 2016: UCLA researchers identify protein that could prevent tumor growth in cervical cancer 79
May 02, 2016: TGen SU2C Melanoma Dream Team Member Receives $200,000 Sharp Award 80
Apr 22, 2016: Widely used class of chemotherapy drugs does not lead to cognitive decline for women with breast cancer 83
Apr 13, 2016: Experimental therapy for brain cancer developed by UCLA and Caltech could prevent drug resistance 84
Apr 04, 2016: To treat a leading cause of osteoporosis, surgery is better than widely used medications 86
Mar 30, 2016: Spinal cord regeneration might actually be helped by glial scar tissue, contrary to conventional wisdom 87
Mar 28, 2016: New drug combinations could significantly improve tuberculosis treatment 89
Mar 22, 2016: UCLA stem cell researcher receives $7.6 million grant 90
Feb 10, 2016: Remote telemonitoring does not reduce hospital readmissions for heart failure patients 91
Feb 04, 2016: Standard method for deriving stem cells may be better for use in regenerative medicine 92
Product News 93
Oct 03, 2017: New method to measure cell stiffness could lead to improved cancer treatments 93
Jun 07, 2016: NantWorks Announces Breakthrough Nano-Thermal Blade Technology to Treat Rare Diseases Through Single Cell Surgery Enabling Mitochondria Transfer into Mammalian Cells 94
May 01, 2017: Combination therapy could provide new treatment option for ovarian cancer 95
Apr 04, 2017: Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles 97
Apr 04, 2016: UCLA Technology Key to Assessing PTSD in Children and Adolescents, Improves Patient Care Across the Globe 98
Jan 24, 2017: New tuberculosis therapy could be more potent than current treatments 99
Appendix 101
Methodology 101
About GlobalData 101
Contact Us 101
Disclaimer 101
University of California Los Angeles, Pharmaceuticals & Healthcare, Key Facts 2
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of California Los Angeles, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of California Los Angeles, Deals By Therapy Area, 2011 to YTD 2017 9
University of California Los Angeles, Medical Devices Deals, 2011 to YTD 2017 10
University of California Los Angeles, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
InvVax Receives Rights to Vaccine Technology from University of California, Los Angeles 13
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 14
Trethera Enters into Research Agreement with University of California, Los Angeles 16
Bristol-Myers Squibb Enters into Research Agreement with UCLA 17
BioNano Genomics Enters into Research Agreement with University of California, Los Angeles 18
Zymeworks Enters into Research Agreement with University of California, Los Angeles 19
NanoSmart Pharma Enters Into Research Agreement With UCLA For Pediatric Cancer Drug Development 20
F. Hoffmann-La Roche Enters Into Co-Development Agreement With UCLA's Jonsson Comprehensive 21
UCLA Medical Center Forms Joint Venture With First Affiliated Hospital Of Medical School 22
Diamyd Medical Enters into Licensing Agreement with University of California 23
Klyss Biotech Receives Rights to Antibody from University of California, Los Angeles 24
Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 25
Max Biopharma Enters Into License Agreement With UCLA And Johns Hopkins University For Small Molecule Technology 26
Diamyd Medical Expands Licensing Agreement with University Of California, Los Angeles 27
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 28
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 29
Fibrocell Science Enters Into Licensing Agreement With University of California 30
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 31
University of California Los Angeles, Key Competitors 33
University of California Los Angeles, Key Employees 34
University of California Los Angeles, Subsidiaries 35
University of California Los Angeles, Joint Venture 37
【免責事項】
http://www.globalresearch.jp/disclaimer